Seegene has launched the Global Million Clinical Study (GMCS), aiming to evaluate the clinical utility and potential impact of comprehensive syndromic PCR testing approaches using real-world data.

This project is scheduled to begin in South Korea and at healthcare institutions across the world to accumulate large-scale global testing data and assess the clinical value of disease-specific testing approaches for major infectious diseases. The goal is to build the scientific basis for new global testing standards and support a more comprehensive and accurate diagnostic environment, in which everyone, regardless of country or region, can access the best testing currently available.

For this project, Seegene provides STAgora, a real-time testing data analytics platform. The platform is intended to support statistical analysis of pathogen prevalence and infection trends across disease types and geographic regions.

GMCS aims to go beyond conventional targeted testing and assess the clinical value of comprehensive PCR testing that enables the multiple detection of major causative pathogens in a single test. The study will analyze real-world testing data that has been difficult to fully capture through conventional testing alone, including previously undetected pathogens, co-infections, genotypes, and regional and seasonal epidemiological patterns.  

The study will initially focus on major infectious disease types, including reproductive tract infections, respiratory tract infections and gastrointestinal tract infections. By doing so, the study aims to bring additional testing insights beyond those provided by existing testing methods and assess how this information may support clinical decision-making.

Seegene noted that GMCS is an evidence-generation initiative and does not constitute medical advice, diagnostic guidance or a product-specific performance claim.

Visit Seegene for more information